You are here

Genfit

Ipsen/Genfit eye June FDA verdict for liver drug elafibranor

Pharmaphorum

Thu, 12/7/23 - 11:01 am

primary biliary cholangitis

priority review

Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay

Fierce Biotech

Tue, 11/14/23 - 09:20 am

Intercept Pharma

CymaBay Therapeutics

Ipsen and Genfit to file for EMA and FDA approval for elafibranor

Clinical Trials Arena

Fri, 06/30/23 - 10:12 am

primary biliary cholangitis

Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

Xconomy

Wed, 09/30/20 - 10:58 pm

Genfit abandons late-stage trial of NASH drug elafibranor

Pharmaforum

Thu, 07/23/20 - 10:39 am

clinical trials

Biotech Genfit warns costs of failed NASH trial will drag deep into 2020

Fierce Biotech

Tue, 05/19/20 - 10:29 am

clinical trials

Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study

Xconomy

Mon, 05/11/20 - 11:50 pm

clinical trials

The crucial data readouts coming soon for small biotechs

EP Vantage

Thu, 04/23/20 - 12:37 pm

clinical trials

Blueprint Medicines

TG Therapeutics

Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data

Xconomy

Mon, 04/13/20 - 11:04 am

COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout

Fierce Biotech

Tue, 03/31/20 - 11:04 am

clinical trials

Genfit's NASH key phase 3 data delayed

Fierce Biotech

Fri, 02/21/20 - 10:32 am

clinical trials

#JPM20: After Year of NASH collapses, all eyes on two biotechs

Endpoints

Thu, 01/16/20 - 10:14 am

Gilead Sciences

Will we see the world's first approved NASH drug in 2020?

Fierce Biotech

Fri, 12/20/19 - 10:20 am

Intercept Pharma

As NASH shifts again, the focus remains on Genfit’s big readout

EP Vantage

Wed, 12/18/19 - 10:53 am

Boehringer Ingelheim

Gilead Sciences

Intercept Pharma

Genfit trumpets new NASH blood biopsy data

Pharmaforum

Tue, 11/12/19 - 08:01 pm

Genfit’s liver disease Hail Mary approaches

EP Vantage

Thu, 09/19/19 - 08:10 pm

As Genfit hopes to get its liver drug on the market, founding CEO makes way for new blood

Fierce Biotech

Tue, 09/3/19 - 11:04 am

François Mouney

NASH drugmaker stocks rebound after dip on FDA guidance

Biopharma Dive

Mon, 06/10/19 - 06:08 pm

Madrigal Pharmaceuticals

Viking Therapeutics

Intercept Pharma

GenFit Moves Lead Candidate into Another Phase III Trial with Breakthrough Therapy

BioSpace

Wed, 04/24/19 - 11:58 am

breakthrough therapy

primary biliary cholangitis

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

Yahoo/Benzinga

Mon, 04/22/19 - 10:34 am

Concert Pharmaceuticals

Edwards Lifesciences

Precision Biosciences

Boston Scientific

Bristol-Myers Squibb

Seattle Genetics

Pages